Spanish competition authority CNMC has filed charges against the country’s leading pharmaceuticals, including Pfizer, S.L.U., Janssen-Cilag, S.A., Merck Sharp & Dohme de España S.A., Lilly, S.A., Sanofi-Aventis, S.A. and Novartis Farmacéutica, S.A. over alleged uncompetitive agreements. The companies are suspected of having set up distribution systems geared towards maintaining a double-pricing scheme, as well as agreements between the various laboratories.
The case dates back to a complaint presented by the European Association of Euro Pharmaceutical Companies (EAEPC) in 2007. In 2009 the CNMC’s predecessor, the CNC, decided to dismiss the case, having failed to find any evidence of competition law violations.
The decision by the former regulator was reversed in March 2016, with a resolution reopening the files and urging the CNMC to continue their investigations into the case.
Full Content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
TikTok to Label AI-Generated Content Amid Election Interference Concerns
May 9, 2024 by
CPI
Italy’s Antitrust Authority Imposes Heavy Fines on Car Rental Giants
May 9, 2024 by
CPI
Florida Firefighters’ Pension Fund Settles Lawsuit Against Carl Icahn for $2.2 Million
May 9, 2024 by
CPI
Hermes Fights Back Against ‘Far-Fetched’ Birkin Bag Lawsuit
May 9, 2024 by
CPI
European Music Streaming Firms Rally Against Apple’s Proposed Remedies
May 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI